Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 3Sarcoma, Myeloid 1Myelodysplastic Syndromes 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1

Interventions

venetoclax 27fludarabine 26Cyclophosphamide 25Specimen Handling 21Azacitidine 20Biopsy 15Whole-Body Irradiation 14Stem Cell Transplantation 13Decitabine 13Cytarabine 13Tacrolimus 12Melphalan 12fludarabine phosphate 11Mycophenolic Acid 11Busulfan 11Injections 8X-Rays 7Thiotepa 7Hematopoietic Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7decitabine and cedazuridine drug combination 6Cyclosporine 6ruxolitinib 5Magnetic Resonance Spectroscopy 5Idarubicin 5Filgrastim 5gilteritinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic Syndromes × quizartinib × Clear all
NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
73 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡